文献速递其他结缔组织病

国际硬皮病肾危象调查II:治疗模式与结局的起始队列研究

Treatment patterns and outcomes of scleroderma renal crisis in the international scleroderma renal crisis survey II - An inception cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2026-10-25

该前瞻性国际起始队列纳入97例新发硬皮病肾危象(SRC)患者,分析治疗模式及血压控制时间对预后的影响。结果显示1年死亡率和透析率仍高,血压控制在5-10天者生存最佳,提示控制目标或应宽于专家推荐的72小时。

要点

  • ACE抑制剂使用率达98%,但54%患者需≥3种降压药才能控制血压。
  • 49%患者需透析,1年生存者中25%仍依赖透析。
  • 血压控制时间与最佳生存相关的区间为5-10天,而非72小时。

核心结论

  • SRC的1年死亡率和透析率仍高,血压控制在5-10天与最佳生存相关,提示应重新审视72小时控制目标。

研究设计与样本

  • 前瞻性国际起始队列研究,通过2年网络调查由国际SSc专家识别新发SRC病例,收集2020年1月至2022年1月数据。
  • 共识别97例新发SRC患者,其中83例有1年随访数据。

主要发现

  • 83例随访患者中,中位病程9个月(IQR 5-24),63例(76%)为弥漫性皮肤型,38例(46%)RNA聚合酶III抗体阳性。
  • ACE抑制剂是最常用降压药(98%),但54%患者需≥3种降压药;49%需透析,55例1年生存者中25%仍透析。
  • 1年死亡率39/100人年,血压控制中位时间7天(IQR 3-10),5-10天控制者生存最佳。

关键数值与推荐

  • 血压控制时间与最佳生存相关的区间为SRC起病后5-10天,而非专家推荐的72小时。

临床怎么用

  • SRC治疗中应使用ACE抑制剂,但需注意多数患者需多种降压药联合;血压控制目标可考虑放宽至5-10天以最大化生存。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Scleroderma renal crisis (SRC) is a major cause of morbidity and mortality in systemic sclerosis (SSc). Given its rarity, treatment recommendations are based largely on retrospective studies and expert opinion. OBJECTIVE: We aimed to study treatment patterns and impact of time to control blood pressure in scleroderma renal crisis (SRC). We hypothesized that blood pressure control within 72 h of presentation would be associated with better outcomes. DESIGN: In a prospective, international inception cohort, we collected data on SRC presentation, type of anti-hypertensives, time to control blood pressure, and one-year dialysis and mortality rates. SETTING: New-onset SRC cases were identified via a 2-year web-based survey completed by international SSc experts. Outcomes of interest were collected from January 2020 to January 2022. PARTICIPANTS: SRC cases were identified by physicians with expertise in SSc. MAIN OUTCOME(S) AND MEASURE(S): We recorded all-cause mortality within 12 months of SRC. We compared the survival of subjects by the number of days to control blood pressure using Cox proportional hazards models. RESULTS: We identified 97 subjects with new-onset SRC. Of the 83 with 1-year follow-up, median disease duration was 9 (interquartile range (IQR) 5-24) months, 63 (76%) had diffuse cutaneous disease, and 38 (46%) had RNA polymerase III autoantibodies. ACE inhibitors were the most frequently used anti-hypertensive (98%), but more than half of patients (54%) required ≥ three antihypertensives to control their blood pressure. Almost half of the patients (49%) required dialysis and out of the 55 survivors at one year, 25% remained on dialysis. The one-year incidence mortality rate was 39 per 100 person-years. The median time required to control blood pressure was 7 (IQR 3-10) days. The time to control blood pressure associated with best survival was between 5-10 days after SRC presentation. CONCLUSION AND RELEVANCE: Our data show that 1-year mortality and dialysis rates remain high in SRC and suggest that blood pressure should be controlled within 5-10 days after SRC presentation, as opposed to the expert-recommended 72 h, in order to maximize survival.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Chan R, Baniña M, Berger C, et al. Treatment patterns and outcomes of scleroderma renal crisis in the international scleroderma renal crisis survey II - An inception cohort study. Semin Arthritis Rheum. 2026. PMID: 42966007. doi:10.1016/j.semarthrit.2026.153093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。